|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Tekmira (TKMR) Shareholders Vote For OnCore Biopharma Merger
Shareholders agree to merger with OnCore in a deal that will help Tekmira develop potential cures for hepatitis B
TKMR
By: Hannah Ishmael
Published: Mar 4, 2015 at 4:41 pm EST
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), which is a leading developer of novel RNAi therapeutics, announced on Tuesday that 99.5% of its shareholders have voted in favor of the merger with OnCore Biopharma, Inc. - a deal which will enhance Tekmira’s ability to develop a hepatitis B virus (HBV) cure regimen by using different therapeutic approaches.
Tekmira（TKMR）股东投票支持OnCore生物制药合并
股东同意合并与OnCore的交易，这将有助于Tekmira开发乙肝治疗方法的潜力
TKMR
按：汉娜以实玛利
发布时间：2015年3月4日，在下午4点41 EST
Tekmira制药公司（纳斯达克股票代码：TKMR），这是新的RNAi疗法，周二公布的领先开发商，其股东99.5％的人投票赞成合并与OnCore生物制药公司的 - 该交易将增强Tekmira的能力，开发出乙型肝炎病毒（HBV）的固化方案通过使用不同的治疗方法。
|
|
发表于 2015-3-5 10:39
